Astec Life gains after board approves rights issue of up to <span class='rupeeNews'>R<span>s</span></span> 250-cr

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

04 July 2025 00:00:00

Adani Ports

1424.75

(-0.44%)

Asian Paints

2424.80

(-0.23%)

Axis Bank

1177.55

(0.62%)

Bajaj Finance

925.25

(1.60%)

Bajaj Finserv

1993.80

(0.68%)

Bharat Electro..

427.55

(0.33%)

Bharti Airtel

2017.45

(0.00%)

Eternal Ltd

261.25

(0.21%)

HCL Technologi..

1725.35

(0.86%)

HDFC Bank

1989.25

(0.18%)

Hind. Unilever

2339.80

(1.19%)

ICICI Bank

1442.65

(1.15%)

Infosys

1640.20

(1.36%)

ITC

412.55

(-0.24%)

Kotak Mah. Ban..

2128.40

(0.10%)

Larsen & Toubr..

3593.70

(0.31%)

M & M

3161.75

(-0.41%)

Maruti Suzuki

12648.75

(-0.81%)

NTPC

335.50

(0.21%)

Power Grid Cor..

294.10

(0.14%)

Reliance Indus..

1527.40

(0.56%)

St Bk of India

811.85

(0.59%)

Sun Pharma.Ind..

1676.65

(-0.13%)

Tata Motors

688.95

(-0.21%)

Tata Steel

163.00

(-1.72%)

TCS

3420.95

(0.59%)

Tech Mahindra

1655.05

(-1.07%)

Titan Company

3686.35

(0.19%)

Trent

5448.65

(-11.93%)

UltraTech Cem.

12505.60

(0.90%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

Astec Life gains after board approves rights issue of up to Rs 250-cr	Share Back
(24 Jun 2025)
In a regulatory filing, the company said its board, at a meeting held on Tuesday, 24 June 2025, approved the issuance of fully paid-up equity shares with a face value of Rs 10 each for an amount not exceeding Rs 250 crore. The rights issue will be offered to eligible equity shareholders as of the record date, which will be announced in due course. Astec Lifesciences is into the manufacturing of agrochemical active ingredients (technical), bulk and formulations, and intermediate products, and it sells its products in India as well as exports them to approximately 24 countries. The company’s consolidated net loss widened to Rs 16.08 crore in Q4 FY25 as against a net loss of Rs 0.964 crore reported in Q4 FY24. Revenue from operations declined 22.26% YoY to Rs 119.53 crore in the quarter ended 31 March 2025.
Top